liveBook · Manning

Chapter 1: The Drug Discovery Process

What you will learn in chapter 1 of Build AI Drug Discovery Pipelines

The chapter introduction explains why drug discovery is difficult and why computational screening and machine learning are useful.

After this chapter you will be able to

Section by section

Introduction

The chapter introduction explains why drug discovery is difficult and why computational screening and machine learning are useful.

Key terms: drug-like molecules, drug candidates, clinical trial, computational approaches, machine learning, screening, drug candidate safety

1.1 The Challenge of Drug Discovery

Introduces the challenges that motivate machine learning in drug discovery and notes that practical pipelines depend on interdisciplinary collaboration.

Key terms: interdisciplinary, vocabularies, success criteria, communication, tooling

1.1.1 Needle in a Haystack

This section frames drug discovery as a vast search for molecules that act on biological targets, then explains why binding, experimental data, and other failure modes make that search difficult.

Key terms: chemical search space, brute-force search, machine learning, biological search space, targets, proteoforms, conformations, free energy, binding affinity, assays

1.1.2 Eroom’s Law

The section explains Eroom’s Law, why its apparent reversal needs careful interpretation, and how risk-averse drug discovery strategies and AI fit into that picture.

Key terms: Eroom’s Law, R&D efficiency, FDA drug approvals, PhRMA member companies, oncology, rare disease, expedited pathways, me-too drugs, follow-on drugs, newer modalities

1.1.3 The Regulatory Landscape

This section explains how FDA approval and successive clinical-trial phases constrain whether a promising drug candidate can reach patients.

Key terms: FDA, regulatory gatekeeper, safety, efficacy, FDA approval, preclinical testing, Phase 1, Phase 2, Phase 3, standard of care

1.2 The Language of Molecules

This introduction frames molecular representation as the bridge between small molecules and machine-learning models in drug discovery.

Key terms: molecule, representations, input data, ML models, small molecules, practical on-ramp

1.2.1 What is a Molecule? The Joy of SMILES

This section introduces molecules and the two computational representations used throughout the book: SMILES strings and molecular graphs.

Key terms: molecule, compound, covalent bonds, noncovalent bonds, SMILES, atomic symbols, brackets, bond symbols, implicit bonds, canonical SMILES

1.2.2 What is Machine Learning?

The section explains how machine learning learns from examples, why it must generalize to new molecules, and how supervised and unsupervised learning differ.

Key terms: artificial intelligence, machine learning, deep learning, artificial neural networks, training set, training instance, training phase, inference, prediction phase, test set

1.2.3 An Example Application with USAN Stems & RDKit

The section uses RDKit to turn drug structures into numerical features, then illustrates unsupervised exploration and supervised classification of drugs by USAN stem.

Key terms: RDKit, molecule object, Mol, ROMol, SMILES, molecular fingerprint, ECFP6, bit vector, substructures, PCA

1.3 Deep Learning’s Value Proposition

This introduction previews drug discovery applications of deep learning that the following sections will discuss.

1.3.1 Virtual Screening & Property Prediction

The section explains how virtual screening prioritizes drug candidates, contrasts physics-based and ML-based approaches, and describes the benefits and limits of screening at scale.

Key terms: virtual screening, drug candidates, experimental screening, molecular docking, ligand, binding affinity, ML-based virtual screening, molecular representations, SMILES, molecular graph

1.3.2 Generative Chemistry

The section contrasts de novo molecular design with virtual screening and explains both the promise and limitations of AI-generated drug candidates.

Key terms: de novo design, generative chemistry, virtual screening, functional space, chemical space, scoring function, property-prediction models, reward hacking, hand-crafted chemical features, feature engineering

1.3.3 Chemical Reaction Prediction & Retrosynthesis

This section explains why novel drug designs need synthesis plans, how retrosynthesis works backward from a product, and why its large search space motivates automated planning.

Key terms: de novo drug design, synthetic chemistry, forward synthesis, retrosynthesis, reactants, product, chemical search space, transformations, heuristics, rule-based synthesis planning tools

1.3.4 Protein Folding & Simulations

This section explains why protein structure matters, how deep learning helps predict it, and how molecular dynamics adds information about protein motion.

Key terms: amino acids, sidechains, protein structure, 3D structure, protein folding problem, AlphaFold2, deep learning, predicted structure, molecular dynamics (MD) simulations, static snapshot

1.4 Introducing Drug Discovery

This section maps the phases of drug discovery and distinguishes them from the clinical and regulatory steps of drug development.

Key terms: target identification or selection, target-to-hit, hit discovery, hit-to-lead, lead identification, lead optimization, drug discovery, drug development, clinical trials, FDA

1.4.1 Target Identification & Hit Discovery

The section explains how researchers choose and validate a disease-related target, find compounds that bind it, and consider how those compounds act and where else they might act.

Key terms: target identification, biomolecule target, validate, computational tools, large language model agents, candidate targets, hit, binding affinity, compound library, virtual screening

1.4.2 Lead Identification & Lead Optimization

This section explains how hits become leads, how leads are optimized for therapeutic properties, and what happens before clinical testing.

Key terms: hits, leads, lead identification, ADMET screening, pharmacokinetic (PK), pharmacodynamic (PD), lead optimization, core molecular structure, efficacy, activity

1.4.3 Drug Development

This section traces drug candidates through clinical trials and expedited approval, then connects earlier modeling examples to the book’s broader drug-discovery workflow.

Key terms: Phase I, Phase II, Phase III, safety, efficacy, risk-benefit profile, expedited approval, conditional market approval, first-in-class drugs, orphan drugs

1.5 Summary

Where this is used later

Concepts explained in this chapter

Chapter 2: Ligand-based Screening: Filtering & Similarity Searching →

These guides are generated from the text of Manning books by Manning's knowledge graph and link to the sections they draw on. The full books are available on liveBook and at manning.com.